Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients

[1]  T. Sugino,et al.  Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system. , 2022, Japanese journal of clinical oncology.

[2]  K. Oda,et al.  Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey , 2022, Journal of Human Genetics.

[3]  M. Sekine,et al.  Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan , 2022, Journal of Human Genetics.

[4]  H. Ono,et al.  Efficacy of endoscopic samplings during initial biliary drainage for cases of pancreatic head cancer: United diagnostic yields of multiple pathological samplings. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[5]  A. Biankin,et al.  Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Kang,et al.  Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. , 2021, Annals of hepato-biliary-pancreatic surgery.

[7]  I. Sahin,et al.  A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2 , 2021, Molecular Biology Reports.

[8]  C. Kang,et al.  Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[9]  W. Foulkes,et al.  Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. , 2021, European journal of cancer.

[10]  B. Karlan,et al.  Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  R. Yamashita,et al.  Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies , 2020, Nature Medicine.

[12]  Y. Kamatani,et al.  Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes , 2020, EBioMedicine.

[13]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[14]  Seigo Nakamura,et al.  Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X , 2019, Oncotarget.

[15]  S. Akashi-Tanaka,et al.  BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ , 2019, Molecular genetics & genomic medicine.

[16]  M. Sekine,et al.  Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan , 2017, Journal of Human Genetics.

[17]  T. Kawaguchi,et al.  Familial pancreatic cancer: Concept, management and issues , 2017, World journal of gastroenterology.

[18]  O. Olopade,et al.  Effect of BRCA germline mutations on breast cancer prognosis , 2016, Medicine.

[19]  R. Tollenaar,et al.  Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis , 2014, International journal of cancer.

[20]  K. Kosaki,et al.  Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future. , 2013, Japanese journal of clinical oncology.

[21]  E. Rosenthal,et al.  Clinical significance of large rearrangements in BRCA1 and BRCA2 , 2012, Cancer.

[22]  Y. Miki.  [Cellular functions of BRCA genes - from basic science to therapeutics]. , 2012, Gan to kagaku ryoho. Cancer & chemotherapy.

[23]  E. V. Rensburg,et al.  Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation , 2010, Breast Cancer Research and Treatment.

[24]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[25]  A. Basu,et al.  New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. , 2009, The Lancet. Oncology.

[26]  日本膵臓学会.  Classification of pancreatic carcinoma , 2003 .

[27]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.